Slow acceptance of model-informed biopharmaceutical development
Demand for Certara’s software and services depends on regulators and customers continuing to embrace biosimulation and MIDD.
- Scope
- Core demand driver
- Materiality
- high
Certara, Inc.
Certara, Inc. builds biosimulation software and technology-enabled consulting services used in drug discovery and development. The company’s tools help biopharmaceutical teams apply model-informed drug development (MIDD) to predict outcomes, reduce development risk, and support regulatory submissions. Its platform is used across the life sciences value chain, from early research through clinical development and regulatory review. Certara also sells software to global drug regulators and provides project-based scientific services delivered by experienced drug-development specialists. The business is anchored in the adoption of quantitative modeling in life sciences rather than in traditional enterprise software workflows.
23,0 %
−0,4 %
+8,7 %
2.05
2.05
| % | |
|---|---|
| Software licenses | 30% Perpetual or term licenses for validated biosimulation applications delivered upfront. |
| Software subscriptions | 35% Cloud-based access and support for Certara software recognized ratably over the contract term. |
| Maintenance and support | 10% Ongoing support, updates, and maintenance tied to installed software and subscriptions. |
| Consulting and technology-enabled services | 25% Scientist-led project work that applies biosimulation and MIDD to customer programs. |
Certara sells primarily to biopharmaceutical and biotech companies that use its software and services to improve R&D...
- Biopharmaceutical companiesprimary
Buy biosimulation software and consulting to improve R&D productivity, support filings, and reduce development risk.
- Biotech companiesprimary
Use the platform for model-informed development with limited internal resources and high pipeline uncertainty.
- Contract research organizationssecondary
Purchase software and services to execute modeling and simulation work on behalf of sponsor clients.
- Regulators and government agenciessecondary
License software for scientific review, assessment, and decision support in drug regulation.
- Academic and public sector institutionssecondary
Use the tools for research, training, and translational science applications.
- Adjacent life sciences industriesemerging
Buy selected software and services for animal health, crop science, bio science, and medical devices.
Certara operates globally and says its solutions have been used by customers in more than 70 countries...
- •Global customer base across more than 70 countries
- •Strong exposure to the United States through FDA-related use cases
- •European presence through EMA and UK MHRA regulatory adoption
- •Asia exposure through Japan PMDA and China CDE usage
- •International expansion supported by direct sales and distributors
- •No country-level revenue split disclosed in the excerpts
Certara’s strategy is to expand the breadth and depth of its biosimulation platform across the drug-development...
01
Broaden the platform with new software and servicesmedium-term
A wider product set increases wallet share and makes Certara more embedded in customer workflows.
02
Expand international commercial reachmedium-term
Growth depends on adoption across more geographies and regulatory systems.
03
Drive regulatory and scientific acceptance of MIDDlong-term
Regulatory support is a key demand driver for biosimulation in drug development.
04
Pursue acquisitions and complementary businessesmedium-term
Acquisitions can add capabilities, customers, and cross-sell opportunities.
Certara’s demand depends on continued acceptance of model-informed drug development by regulators, academic...
Customer consolidation in biopharma
Mergers can reduce the number of licenses and users, and merged companies may negotiate lower prices.
- Scope
- Large pharma customer base
- Materiality
- high
Cybersecurity and service disruption
The company relies on software applications and IT systems that could be affected by cyberattacks, outages, or failures.
- Scope
- Cloud/software operations
- Materiality
- high
Compliance with anti-bribery and public-sector rules
Sales to regulators and foreign government-related entities increase exposure to FCPA, Bribery Act, and procurement compliance.
- Scope
- Government and international sales
- Materiality
- medium
Revenue recognition for licenses, subscriptions, maintenance, and services
Important for quarterly comparability and backlog interpretation
Seasonality and renewal timing
Affects quarterly run-rate analysis
Organic revenue and acquisition adjustments
Important for assessing core operating momentum
Valuation allowance and tax estimates
Can create volatility in reported earnings
Septerna, Inc.
SEPN · Pharmaceutical Preparations
Septerna is a U.S.-based biotechnology company focused on discovering and developing small-molecule medicines for diseases driven by G protein-coupled receptors (GPCRs).
LISATA THERAPEUTICS, INC.
LSTA · Pharmaceutical Preparations
Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing certepetide, an investigational therapy designed to improve delivery of anti-cancer drugs into solid tumors.
SECTRA
SECT-B.ST · Health Care
Sectra is a technology company focused on improving healthcare and cybersecurity.
VirTra, Inc
VTSI · Miscellaneous Manufacturing Industries
FinTrade Sherpa, Inc.
FTSP · Gold and Silver Ores
ACCENDRA HEALTH INC/VA/
ACH · Wholesale-Medical, Dental & Hospital Equipment & Supplies
Accendra Health, Inc.
: 28.4.2026